Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)
CNY 19.28
(0.47%)
CNY 19.28
(0.47%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 17.12 Million | 9.71 Million | 59.61 Million | 91.42 Million | 89.73 Million | 65.35 Million |
| Net Income | 21.01 Million | 29.33 Million | 75.28 Million | 83.62 Million | 72.8 Million | 62.41 Million |
| Depreciation & Amortization | 40.99 Million | 35.68 Million | 18.57 Million | 10.46 Million | 11.33 Million | 12.39 Million |
| Deferred income taxes | -10.65 Million | -3.6 Million | 5.77 Million | 1.3 Million | 719.39 Thousand | -1.09 Million |
| Stock-based compensation | 5.83 Million | 7.6 Million | 7.35 Million | - | - | - |
| Change in working capital | -56.6 Million | -69.89 Million | -28.84 Million | -5.96 Million | 2.89 Million | -11.35 Million |
| Other non-cash items | -1.54 Million | 10.59 Million | -18.53 Million | 3.3 Million | 2.71 Million | 1.88 Million |
| Investing Cash Flow | -32.69 Million | -114.92 Million | -446.61 Million | -183.3 Million | -59.78 Million | -46.98 Million |
| Investments in PPE | -37.74 Million | -72.16 Million | -143.34 Million | -62.44 Million | -35.54 Million | -43.91 Million |
| Acquisitions | -1.25 Million | 3.57 Million | -31.85 Million | 62.64 Million | 36.11 Million | -2.5 Million |
| Investment purchases | -220.02 Million | -657.81 Million | -1.11 Billion | -519.18 Million | -192 Million | -232.5 Million |
| Sales/Maturities of investments | 223.39 Million | 612.85 Million | 839.29 Million | 398.12 Million | 167.19 Million | 230.51 Million |
| Other Investing Activities | 6.29 Million | -1.36 Million | 2.92 Million | -62.44 Million | -35.54 Million | 1.42 Million |
| Financing Cash Flow | -6.89 Million | -21.4 Million | -29.52 Million | 639.33 Million | -19.21 Million | -17.13 Million |
| Debt repayment | -6.89 Million | -7 Million | -7 Million | - | - | -600 Thousand |
| Dividends payments | -13.46 Million | -25.2 Million | -26.13 Million | - | -17.5 Million | -16.52 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -324.38 Thousand | 12.21 Million | 3.8 Million | 639.33 Million | 8000.00 | -10 Thousand |
| Accounts receivables | -9.29 Million | -36.17 Million | -35 Million | -20.13 Million | -4.47 Million | -20.86 Million |
| Accounts payables | -6.16 Million | -7.04 Million | 17.02 Million | 26.67 Million | 3.45 Million | 12.01 Million |
| Inventory | -30.48 Million | -23.07 Million | -16.64 Million | -13.8 Million | 3.18 Million | -1.4 Million |
| Other working capital | 5.83 Million | -3.6 Million | 5.77 Million | 1.3 Million | 719.39 Thousand | -9.95 Million |
| Cash at beginning of period | 90 Million | 216.46 Million | 633.04 Million | 85.69 Million | 74.95 Million | 73.73 Million |
| Cash at end of period | 67.61 Million | 90 Million | 216.46 Million | 633.04 Million | 85.69 Million | 74.95 Million |
| Capital Expenditure | -37.74 Million | -72.16 Million | -143.34 Million | -62.44 Million | -35.54 Million | -43.91 Million |
| Effect of forex changes on cash | 79.56 Thousand | 141.94 Thousand | -55.4 Thousand | -101.82 Thousand | 91.06 | -9089.59 |
| Net cash flow / Change in cash | -22.39 Million | -126.46 Million | -416.58 Million | 547.34 Million | 10.73 Million | 1.22 Million |
| Free Cash Flow | -20.62 Million | -62.45 Million | -83.72 Million | 28.97 Million | 54.19 Million | 21.43 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 13.26 Million | 8.37 Million | 7.98 Million | 2.7 Million | 21.01 Million | 19.48 Million |
| Depreciation & Amortization | - | 12.34 Million | 12.34 Million | 12.34 Million | 40.99 Million | -20.21 Million |
| Deferred income taxes | - | -7.81 Million | - | - | -10.65 Million | 12.96 Million |
| Stock-based compensation | - | 3.42 Million | - | 5.83 Million | 5.83 Million | -5.68 Million |
| Change in working capital | - | -20.88 Million | - | -33.94 Million | -56.6 Million | 12.94 Million |
| Other non-cash items | 2.11 Million | 28.33 Million | -32.46 Million | -2.7 Million | -1.54 Million | -3.88 Million |
| Investing Cash Flow | -22.5 Million | 988.3 Thousand | 25.53 Million | -16.84 Million | -32.69 Million | -16.21 Million |
| Investments in PPE | -8.76 Million | -5.59 Million | -17.39 Million | 5.81 Million | -37.74 Million | -25.85 Million |
| Acquisitions | 2.08 Million | 137.35 Thousand | 478.7 Thousand | -3.98 Million | -1.25 Million | 4.64 Million |
| Investment purchases | -39.28 Million | -8 Million | -12.31 Million | -42.94 Million | -220.02 Million | -65.7 Million |
| Sales/Maturities of investments | 25.42 Million | 14.44 Million | 54.77 Million | 24.27 Million | 223.39 Million | 71.94 Million |
| Other Investing Activities | 110.21 Thousand | 2.11 Million | 42.93 Million | -21.4 Million | 6.29 Million | -1.25 Million |
| Financing Cash Flow | -4.64 Million | -8.85 Million | -20.37 Million | 8.99 Million | -6.89 Million | 5.49 Million |
| Debt repayment | -1 Million | -6.8 Million | -20 Million | -8.89 Million | -6.89 Million | -5 Million |
| Dividends payments | -1.78 Million | -14.03 Million | -19.74 Thousand | -13.06 Million | -13.06 Million | -13.06 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.85 Million | -547.64 Thousand | -354.78 Thousand | 232.47 Thousand | -324.38 Thousand | 10.64 Million |
| Accounts receivables | - | -12.48 Million | - | -9.29 Million | -9.29 Million | 3.17 Million |
| Accounts payables | - | - | - | - | -6.16 Million | - |
| Inventory | - | -11.82 Million | - | -30.48 Million | -30.48 Million | 9.76 Million |
| Other working capital | - | 3.42 Million | - | 5.83 Million | 5.83 Million | - |
| Cash at beginning of period | 56.97 Million | 48.3 Million | 67.61 Million | 61.38 Million | 90 Million | 58.44 Million |
| Cash at end of period | 44.76 Million | 57.01 Million | 48.3 Million | 67.61 Million | 67.61 Million | 61.38 Million |
| Capital Expenditure | -8.76 Million | -5.59 Million | -17.39 Million | 5.81 Million | -37.74 Million | -25.85 Million |
| Effect of forex changes on cash | 643.67 | -11.43 Thousand | -12.00 | 158.26 Thousand | 79.56 Thousand | -1.94 Million |
| Net cash flow / Change in cash | -12.2 Million | 8.71 Million | -19.31 Million | 6.22 Million | -22.39 Million | 2.94 Million |
| Free Cash Flow | 6.61 Million | 10.95 Million | -41.87 Million | 18.31 Million | -20.62 Million | -10.24 Million |
YARIY
600223
688018
GEMD
605081
0R33